Samrat Pharmachem Share Price
237.50+0.65 (+0.27%)
-24.75% past 1 Year
Samrat Pharmachem Ltd is is currently engaged in manufacturing iodine salts & bromine salts.The finished products produced by the company are used in various industries like Pharmaceuticals, Chemicals, Food, Fertilizer,
Corporate filings & documents
Announcements
Notice of 34th AGM - Newspaper Publication
2 days agoNotice of 34th AGM - Newspaper Publication
2 days agoThe Register of Members and Share Transfer books will remain closed from September 20 2026 To September 22 2026 (both days inclusive)
1 week agoThe Register of Members and Share Transfer books will remain closed from September 20 2026 To September 22 2026 (both days inclusive)
1 week ago34th Annual General Meeting of the company will be held on Wednesday September 23 2026 at 1:00 PM (IST) through Video Conferencing (VC) / Other Audio Video Means (OAVM)
1 week ago34th Annual General Meeting of the company will be held on Wednesday September 23 2026 at 1:00 PM (IST) through Video Conferencing (VC) / Other Audio Video Means (OAVM)
1 week ago34th Annual Report for the Financial Year 2025-26
1 week ago34th Annual Report for the Financial Year 2025-26
1 week agoNewspaper Publication of extract of Standalone Unaudited Financial Results for the quarter ended June 30 2026.
2 weeks agoNewspaper Publication of extract of Standalone Unaudited Financial Results for the quarter ended June 30 2026.
2 weeks agoThe Board considered and adopted the unaudited financial results for the quarter ended June 30 2026
2 weeks agoThe Board considered and adopted the unaudited financial results for the quarter ended June 30 2026
2 weeks agoAppointment of Statutory Auditors for the company from 34th Annual General Meeting to 39th Annual General Meeting
1 month agoAppointment of Statutory Auditors for the company from 34th Annual General Meeting to 39th Annual General Meeting
1 month agoCertificate under Reg. 74(5) of SEBI (DP) Regulations for the quarter ended 30th June 2026
1 month agoCertificate under Reg. 74(5) of SEBI (DP) Regulations for the quarter ended 30th June 2026
1 month agoSamrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Approval of Un-Audited Financial Results for the quarter ended June 30 2026
2 months agoSamrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Approval of Un-Audited Financial Results for the quarter ended June 30 2026
2 months agoIntimation of Closure of Trading Window for the quarter ended June 30 2026
2 months agoIntimation of Closure of Trading Window for the quarter ended June 30 2026
2 months agoIntimation of Closure of Trading Window for the quarter ended June 30 2026
2 months agoIntimation of Closure of Trading Window for the quarter ended June 30 2026
2 months agoNewspaper Publication of Extract of the Standalone Audited Financial Results for the year ended March 31 2026.
3 months agoNewspaper Publication of Extract of the Standalone Audited Financial Results for the year ended March 31 2026.
3 months agoThe Board considered and adopted the financial results for the quarter and year ended March 31 2026
3 months agoThe Board considered and adopted the financial results for the quarter and year ended March 31 2026
3 months agoAudited Financial Results for the quarter and year ended 31st March 2026
3 months agoAudited Financial Results for the quarter and year ended 31st March 2026
3 months agoAnnual Secretarial Compliance for the year ended 31-March-2026
3 months agoAnnual Secretarial Compliance for the year ended 31-March-2026
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Samrat Pharmachem Ltd-</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230GJ1992PLC017820</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>-</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Nishant Kankaria <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Rajesh Mehta <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 07/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
5 months agoCertificate u/r 74(5) for the quarter ended March 31 2026
5 months agoCertificate u/r 74(5) for the quarter ended March 31 2026
5 months agoCrisil Limited has upgraded its rating to CRISIL BB/STABLE/ CRISILA4+
5 months agoCrisil Limited has upgraded its rating to CRISIL BB/STABLE/ CRISILA4+
5 months agoClosure of Trading Window from 01-04-2026 till 48 hours after the declaration of Audited Financial Results for the year ended 31/03/2026
5 months agoSamrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve the Audited Financial Results for the year ended March 31 2026
5 months agoSamrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve the Audited Financial Results for the year ended March 31 2026
5 months agoNewspaper Publication - Extract of Un-audited financial results for the quarter ended 31 December 2025
6 months agoNewspaper Publication - Extract of Un-audited financial results for the quarter ended 31 December 2025
6 months agoThe Board has considered and took on record the Un-audited financial results of the company for the quarter ended December 31 2025.
6 months agoThe Board has considered and took on record the Un-audited financial results of the company for the quarter ended December 31 2025.
6 months agoThe Board has considered and took on record the un-audited standalone financial results for the quarter ended December 31 2025.
6 months agoCertificate u/r 74(5) for the quarter ended 31/12/2025
7 months agoSamrat Pharmachem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve the un-audited financial results for the quarter ended December 31 2025
8 months agoThe Trading Window of the Company shall remain closed from Thursday January 1 2026 till 48 hours after the declaration of Un-audited financial results for the quarter ended December 31 2025.
8 months agoCrisil Ltd has downgraded its rating to "CrisilBB+/Negative/CrisilA4+"
9 months agoNewspaper Publication - Extract of Results for the quarter and half year ended September 30 2025
9 months agoUn-audited financial results for the quarter and half year ended 30th September 2025
9 months agoThe Board of Directors considered and took on record the Un-audited Standalone Financial Results for the quarter and half year ended September 30 2025.
9 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
2025-09-18
Dividend
1.0
2024-09-19
Dividend
1.0
2023-09-18
Dividend
1.0
Company details
Registered office
Plot No A2 / 3445 G I D C, Phase 4 Opp. P C I Ankleshwar Gujarat PIN: 393002 Tel No: 07045456789 / 07046456789 Fax No: 02646- 251291 Email: [email protected] Internet: www.samratpharmachem.com
Registrars
C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai(Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra C 101, 247 Park LBS Marg Vikhroli (West) PIN: Tel No: +91 810 811 8484 Fax No: 91-022-49186060 Email: [email protected] Internet: https://in.mpms.mufg.com/
Management
Nishant Kankaria, Company Secretary & Compliance Officer
Lalit Mehta, Chairman & Managing Director
Lalit Mehta, Chairman & Managing Director
Rajesh Mehta, Whole Time Director
Megh Mehta, Whole Time Director
Renu Dharod, Non Executive Independent Director
Megha Jain, Non Executive Independent Director
Manishkumar Pipalia, Non Executive Independent Director
Sachin Kothary, Non Executive Independent Director
Piyush Dharod, Non Executive Independent Director
Details
BSE 530125
NSE NULL
ISIN INE103E01016